Home > Insider Trading > Filing (0000950170-24-011487)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1701108	Spero Therapeutics Inc.	SPRO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1782817	Sath Shukla	C/O Spero Therapeutics, Inc. 675 Massachusetts Avenue, 14Th Floor Cambridge MA 02139	Ceo And President	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-02-01	679,501	$0.00	1,252,001	No	4	A	Direct
Common Stock	Disposition	2024-02-02	30,901	$1.37	1,221,100	No	4	S	Direct
Common Stock	Disposition	2024-02-05	45,093	$1.45	1,176,007	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2025, subject to the Reporting Person's continued service through the applicable vesting date.
The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2022 and February 1, 2023 pursuant to a "sell to cover" provision included in each RSU Agreement.
Represents the weighted average sales price per share. The shares sold at prices ranging from $1.36 to $1.42 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
The reported transaction is a sale of common stock pursuant to a preexisting 10b5-1 plan upon the vesting of RSUs that were granted to the Reporting Person on February 1, 2022 and February 1, 2023.